Table 3. Association of SF mutation with other gene mutations.
| Variables | No. of patients with alteration (%) | P value | ||
|---|---|---|---|---|
| Whole cohort (n = 500) | SF-mutated patients (n = 54) | SF-wild patients (n = 446) |
||
| FLT3/ITD | 113 (22.6) | 7 (13.0) | 106 (22.7) | 0.0848 |
| FLT3/TKD | 38 (7.6) | 2 (3.7) | 36 (8.1) | 0.4116 |
| NRAS | 61 (12.2) | 7 (13.0) | 54 (12.1) | 0.8266 |
| KRAS | 16 (3.2) | 2 (3.7) | 14 (3.1) | 0.6874 |
| PTPN11 | 18 (3.6) | 3 (5.6) | 15 (3.3) | 0.4291 |
| KIT | 15 (3.0) | 0 (0) | 15 (3.3) | 0.3891 |
| JAK2 | 3 (0.6) | 0 (0) | 3 (0.7) | >0.9999 |
| WT1 | 33 (6.6) | 1 (1.9) | 32 (7.2) | 0.239 |
| NPM1 | 103 (20.6) | 6 (11.1) | 97 (21.7) | 0.0753 |
| CEBPA | 66 (13.2) | 7 (13.0) | 59 (13.2) | >0.9999 |
| RUNX1 | 62 (12.4) | 17 (31.5) | 45 (10.1) | <0.0001 |
| MLL/PTD | 27 (5.4) | 3 (5.6) | 24 (5.4) | >0.9999 |
| ASXL1 | 50 (10.0) | 15 (27.8) | 35 (7.8) | <0.0001 |
| IDH1 | 27 (5.4) | 3 (5.6) | 24 (5.4) | >0.9999 |
| IDH2 | 55 (11) | 11 (20.4) | 44 (9.9) | 0.0344 |
| TET2 | 66 (13.2) | 15 (27.8) | 51 (11.4) | 0.0022 |
| DNMT3A | 70 (14.0) | 9 (16.7) | 61 (13.7) | 0.5353 |
| TP53 | 35 (7.0) | 2 (3.7) | 33 (7.4) | 0.409 |